RJA
CODX

Raymond James & Associates’s Co-Diagnostics CODX Stock Holding History

Raymond James & Associates’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-357
Closed -$34K – 3942
2022
Q3 		$34K Sell
357
-274
-43% -$38.3K ﹤0.01% 3745
2022
Q2 		$106K Buy
+631
New +$96K ﹤0.01% 3673

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return

Raymond James & Associates's CODX Position: Q4 2022 in Review

Raymond James & Associates sold out of Co-Diagnostics (CODX) in Q4 2022, closing a stake of 357 shares — an estimated $34K sold.

Raymond James & Associates first reported a position in CODX in Q2 2022 and held it in 2 quarters. The position peaked at $106K in Q2 2022. 60 funds tracked by Wall St. Rank hold CODX as of Q4 2022.

  • Raymond James & Associates reported no remaining Co-Diagnostics position as of Q4 2022 after selling out during the quarter.
  • Raymond James & Associates sold 357 Co-Diagnostics shares in Q4 2022, an estimated $34K.
  • Raymond James & Associates first reported a position in Co-Diagnostics in Q2 2022 and held it in 2 quarters.
  • Raymond James & Associates's Co-Diagnostics position peaked at $106K in Q2 2022.
  • 60 funds tracked by Wall St. Rank held Co-Diagnostics as of Q4 2022.

Based on Raymond James & Associates's 13F filing for Q4 2022, filed 8 Feb 2023.